Table Garlic supplements and colorectal cancer risk. Main characteristics of studies included in the CUP SLR dose-response analysis Cases/ Author, Year, Study name, Study size Case Exposure RR (95%CI) Adjustment WCRF Code, Outcome Comparison characteristics Follow-up ascertainment assessment Ptrend factors Country (years) Age, alcohol Meng, 2013 NHS, 302/ Biennial Questionnaire Incidence, consumption, COL40930 Prospective 76 208 up proximal cancer yes vs no 0.75 (0.44-1.27) aspirin use, beef, Cohort, 24 years questionnaires pork or lamb as Age: 30-55 and medical 153/ Incidence, distal a main dish, years, records yes vs no 0.68 (0.32-1.48) cancer BMI, calcium W, Intake, nurses 115/ Incidence, rectal yes vs no 0.69 (0.28-1.71) endoscopy, cancer energy, folate, 578/ Incidence, history of cancer colorectal cancer, HRT use, physical yes vs no 0.72 (0.46-1.11) activity, processed meat, smoking, vitamin d Meng, 2013 HPFS, 559/ Incidence, Biennial Questionnaire COL40931 Prospective 45 592 colorectal cancer yes up vs no 1.22 (0.83-1.78) USA 22 Cohort, years questionnaires Age: 40-75 and medical 431/ Incidence, colon years, records yes vs no 1.16 (0.75-1.80) cancer M, Health 200/ Incidence, yes vs no 0.86 (0.40-1.85) professionals proximal cancer 141/ Incidence, distal yes vs no 1.87 (1.01-3.46) cancer
Table Garlic supplements and colorectal cancer risk. Main characteristics of studies included in the CUP SLR dose-response Author, Year, WCRF Code, Country Study name, characteristics Cases/ Study size Follow-up (years) Case ascertainment Exposure assessment Outcome Comparison RR (95%CI) Ptrend Adjustment factors Meng, 2013 COL40930 NHS, Prospective Cohort, Age: 30-55 years, W, nurses 302/ 76 208 24 years Biennial questionnaires and medical records Questionnaire Incidence, proximal cancer yes vs no 0.75 (0.44-1.27) Age, alcohol consumption, aspirin use, beef, pork or lamb as a main dish, BMI, calcium Intake, endoscopy, energy, folate, history of colorectal cancer, HRT use, physical activity, processed meat, smoking, vitamin d 153/ Incidence, distal cancer yes vs no 0.68 (0.32-1.48) 115/ Incidence, rectal cancer yes vs no 0.69 (0.28-1.71) 578/ Incidence, cancer yes vs no 0.72 (0.46-1.11) Meng, 2013 COL40931 USA HPFS, Prospective Cohort, Age: 40-75 years, M, Health professionals 559/ 45 592 22 years Biennial questionnaires and medical records Questionnaire Incidence, colorectal cancer yes vs no 1.22 (0.83-1.78) 431/ Incidence, colon cancer yes vs no 1.16 (0.75-1.80) 200/ Incidence, proximal cancer yes vs no 0.86 (0.40-1.85) 141/ Incidence, distal cancer yes vs no 1.87 (1.01-3.46) up up analysis